Vertex Pharmaceuticals Inc (VRTX) income statement
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)
Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –
Vertex Pharmaceuticals Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 86.0%
- Operating margin
- 38.0%
- Net margin
- 35.0%
- Return on equity, FY2025
- 22.5%
Financial strength
- Current ratio
- 3.19
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 156.0%
Valuation
- P/E ratio
- 31.1
- Price to sales
- 10.76
- Price to book
- 6.69
- Dividend yield
- –
See a number that looks wrong?